Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.93 |
| ▸ | JAK2 | O60674 | 14/20 | 0.93 |
| ▸ | JAK1 | P23458 | 1/20 | 0.92 |
| ▸ | TYK2 | P29597 | 1/20 | 0.92 |
| ▸ | JAK3 | P52333 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716799 | 0.96 | SYK (1.00) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL14716645 | 0.96 | SYK (1.00) | SYKJAK2JAK1TYK2JAK3 | |
| Gusacitinib SCHEMBL29467492 | 0.96 | SYK (1.00) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL14717827 | 0.96 | JAK2 (0.86) | SYKJAK2JAK1TYK2JAK3 | |
| Gusacitinib SCHEMBL14717111 | 0.96 | SYK (1.00) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL20357871 | 0.96 | SYK (0.86) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL14717926 | 0.96 | SYK (0.86) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL14716601 | 0.96 | JAK2 (0.87) | SYKJAK2JAK1TYK2JAK3 | |
| Gusacitinib SCHEMBL25373888 | 0.95 | SYK (0.98) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL14717189 | 0.95 | JAK2 (1.00) | SYKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885JAK1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.